Evaluating probiotic properties of gut microflora for gut modulation as an adjuvant therapy for Parkinson's disease

IF 5.2 Q1 FOOD SCIENCE & TECHNOLOGY
{"title":"Evaluating probiotic properties of gut microflora for gut modulation as an adjuvant therapy for Parkinson's disease","authors":"","doi":"10.1016/j.jfutfo.2024.07.010","DOIUrl":null,"url":null,"abstract":"<div><div>Parkinson's disease (PD) is a neurodegenerative disease. It is not curable and treatment revolves around controlling the symptoms. The most preferable approach is medicating with levodopa drug. One of the major concerns in treating with this drug is its conversion to dopamine within the gut and 1%−10% of dopamine becomes available to the brain, thus compromising the effectiveness of the treatment. Other dominant concerns are <em>γ</em>-amino butyric acid (GABA) collapse and serotonergic dysfunction that leads to secondary symptoms. To counter-balance its appalling repercussions reversal of gut bacterial dysbiosis, gut modulation by supportive bacteria is the new uproar, uncovering potent applications. In this study, gut bacteria were focused on having the ability to overcome the drug interference possibility. Samples were collected from PD patients, prone to PD, and healthy individuals for isolation of gut bacteria and were screened for criteria like tyrosine decarboxylase, GABA, short chain fatty acids (SCFAs), and serotonin production. Thin layer chromatography (TLC), Fourier transform infrared spectroscopy (FTIR), and spectrophotometric analysis were used to test bacteria for the production of GABA and serotonin. A total of 855 isolates were screened and 23 isolates were further evaluated for their probiotic properties. Out of which 6 isolates namely HFS 2.1 TM, HFS 10.2 TM, FS 9.2 SA, HFS 6.2 NA, HFS 11.1 TM, and HFS 11.1 PDA were identified by 16S rRNA sequencing and were screened positive to be prospective psychobiotic agents that could be employed as adjuvant therapy for PD.</div></div>","PeriodicalId":100784,"journal":{"name":"Journal of Future Foods","volume":null,"pages":null},"PeriodicalIF":5.2000,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772566924000442/pdfft?md5=4dce5de4b3c2b5c7abc3c4fb0dbbf892&pid=1-s2.0-S2772566924000442-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Future Foods","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772566924000442","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"FOOD SCIENCE & TECHNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Parkinson's disease (PD) is a neurodegenerative disease. It is not curable and treatment revolves around controlling the symptoms. The most preferable approach is medicating with levodopa drug. One of the major concerns in treating with this drug is its conversion to dopamine within the gut and 1%−10% of dopamine becomes available to the brain, thus compromising the effectiveness of the treatment. Other dominant concerns are γ-amino butyric acid (GABA) collapse and serotonergic dysfunction that leads to secondary symptoms. To counter-balance its appalling repercussions reversal of gut bacterial dysbiosis, gut modulation by supportive bacteria is the new uproar, uncovering potent applications. In this study, gut bacteria were focused on having the ability to overcome the drug interference possibility. Samples were collected from PD patients, prone to PD, and healthy individuals for isolation of gut bacteria and were screened for criteria like tyrosine decarboxylase, GABA, short chain fatty acids (SCFAs), and serotonin production. Thin layer chromatography (TLC), Fourier transform infrared spectroscopy (FTIR), and spectrophotometric analysis were used to test bacteria for the production of GABA and serotonin. A total of 855 isolates were screened and 23 isolates were further evaluated for their probiotic properties. Out of which 6 isolates namely HFS 2.1 TM, HFS 10.2 TM, FS 9.2 SA, HFS 6.2 NA, HFS 11.1 TM, and HFS 11.1 PDA were identified by 16S rRNA sequencing and were screened positive to be prospective psychobiotic agents that could be employed as adjuvant therapy for PD.
评估肠道微生物菌群的益生菌特性,将肠道调节作为帕金森病的辅助疗法
帕金森病(PD)是一种神经退行性疾病。这种疾病无法治愈,治疗主要围绕控制症状进行。最可取的方法是使用左旋多巴药物。使用这种药物治疗的一个主要问题是,它在肠道内会转化为多巴胺,1%-10%的多巴胺会进入大脑,从而影响治疗效果。其他主要问题包括γ-氨基丁酸(GABA)衰竭和导致继发性症状的血清素功能障碍。为了抵消肠道细菌失调带来的可怕影响,通过支持性细菌调节肠道成为新的热门话题,并揭示了其强大的应用价值。在这项研究中,肠道细菌被重点关注是否有能力克服药物干扰的可能性。研究人员从帕金森氏症患者、帕金森氏症易感者和健康人身上采集样本,分离肠道细菌,并根据酪氨酸脱羧酶、GABA、短链脂肪酸(SCFA)和血清素分泌等标准进行筛选。使用薄层色谱法(TLC)、傅立叶变换红外光谱法(FTIR)和分光光度法检测细菌产生 GABA 和血清素的情况。共筛选出 855 个分离菌株,并进一步评估了 23 个分离菌株的益生特性。通过 16S rRNA 测序鉴定了其中 6 个分离菌株,即 HFS 2.1 TM、HFS 10.2 TM、FS 9.2 SA、HFS 6.2 NA、HFS 11.1 TM 和 HFS 11.1 PDA,结果显示这 6 个分离菌株为阳性菌株,有望成为精神生物制剂,可用作治疗帕金森病的辅助疗法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.80
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信